ReviewiScience2025
Unraveling tumor associated macrophage biology in gynecological cancers for targeted therapy in the single cell omics era.
Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) has long been the subject of cancer research, particularly in deciphering the complicated mechanisms underlying tumor development. Tumor associated macrophages (TAMs), as key components of the TME, exhibit remarkable heterogeneity and drive complex interactions that influence immune evasion and therapeutic resistance. Recent technological advancements, particularly single-cell RNA sequencing, have enabled the precise dissection of TAM subpopulations, offering unprecedented insights into their functional diversity. Gynecological cancers represent a global health burden with high morbidity and mortality. Despite advances in chemotherapy and immunotherapy, treatment efficacy remains suboptimal in advanced-stage patients, underscoring the urgent need to explore cellular mechanisms underlying therapeutic failure. This review aims to summarize emerging evidence on TAM subclusters in gynecological malignancies, highlight the context-dependent phenotypic plasticity of TAMs, point out the phenotype-specific roles in tumor progression and drug resistance and evaluate translational strategies targeting specific subtypes to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.